BiotechTube

Zoster Vaccine, Live (AMP) + Zoster Vaccine, Live

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Herpes Zoster

Conditions

Herpes Zoster, Shingles

Trial Timeline

Apr 1, 2012 → Nov 1, 2012

NCT ID
NCT01505647

About Zoster Vaccine, Live (AMP) + Zoster Vaccine, Live

Zoster Vaccine, Live (AMP) + Zoster Vaccine, Live is a phase 3 stage product being developed by Merck for Herpes Zoster. The current trial status is completed. This product is registered under clinical trial identifier NCT01505647. Target conditions include Herpes Zoster, Shingles.

What happened to similar drugs?

8 of 20 similar drugs in Herpes Zoster were approved

Approved (8) Terminated (1) Active (11)
✅Zoster Vaccine, Live + Comparator: placeboMerckApproved
✅Zoster Vaccine LiveMerckApproved
✅ZOSTAVAX®MerckApproved
✅FamciclovirNovartisApproved
✅Famciclovir + PlaceboNovartisApproved
✅FamciclovirNovartisApproved
✅FamciclovirNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01505647Phase 3Completed

Competing Products

20 competing products in Herpes Zoster

See all competitors
ProductCompanyStageHype Score
mRNA-1608ModernaPhase 2
0
mRNA-1468ModernaPhase 2
0
ASP2151 + Valacyclovir hydrochlorideAstellas PharmaPhase 2
35
ASP2151 + PlaceboAstellas PharmaPhase 1
29
ASP2151 + valacyclovir + PlaceboAstellas PharmaPhase 2
35
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
GSK1349572 + EfavirenzShionogiPhase 1
29
Zoster Vaccine, Live + Comparator: PlaceboMerckPhase 2
35
Comparator: V212 + Comparator: PlaceboMerckPhase 1
29
Zoster Vaccine, LiveMerckPhase 3
40
V212 + PlaceboMerckPhase 3
40
zoster vaccine live (ZOSTAVAX™) + Comparator: PlaceboMerckPhase 3
40
ZOSTAVAXMerckPhase 3
40
V212 + PlaceboMerckPhase 2
35
V212 + Matching placeboMerckPhase 3
40
V212 Lot 1 + V212 Lot 2 + V212 Lot 3MerckPhase 3
32
HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9%MerckPhase 1
21
V212 + PlaceboMerckPhase 1
29
Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ + Comparator: placebo (concomitant-vaccine matched) + Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23MerckPhase 3
40
ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal + ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal + Full Dose Intradermal Placebo + Intradermal PlaceboMerckPhase 1
29